Donatienne Taylor

4PUBLICATIONS
46CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Jul 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN study.

|Dec 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret, Delphine Loirat, Philippe Aftimos

|Nov 03, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Laurence Buisseret, Delphine Loirat, Philippe Aftimos

|May 18, 2022
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.

Francois-Clement Bidard, Virginia G Kaklamani, Patrick Neven

Pageof 1

Frequent Collaborators

3 joint publications

Francois P Duhoux

2 joint publications

Paulus Kristanto

2 joint publications

Emanuela Romano

2 joint publications

Roberto Salgado